Showing session: reset
Biomarkers and Clinical Targeting of the PI3 Kinase and VEGF Pathways
- Sort by:
- Browse by:
- Free
- Unknown permission
for presentation
Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC)
José Baselga
Mass. General Hospital Cancer Center Administration, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Gordon B Mills
UT MD Anderson Cancer Ctr., Houston, TX, United States
- Free
- slides video
- audio + slides
- All slides included
Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors
Udai Banerji
Inst. of Cancer Research, Sutton, United Kingdom
- Free
- audio + slides
- Some slides withheld
Discussant
Carlos L Arteaga
Vanderbilt-Ingram Cancer Ctr., Nashville, TN, United States
- Free
- slides video
- audio + slides
- All slides included
Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor
Jordi Rodon
Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
- Free
- slides video
- audio + slides
- All slides included
Discussant
Lewis C. Cantley
Weill Cornell Medical College, New York, NY, United States
- Free
- Unknown permission
for presentation
GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study
Dejan Juric
Massachusetts General Hospital Cancer Center, Boston, MA, United States
- Free
- audio + slides
- Some slides withheld
Discussant
Sarat Chandarlapaty
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy
Charles S Fuchs
Dana-Farber Cancer Inst., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Herbert I Hurwitz
Duke Univ. Medical Ctr., Durham, NC, United States